-+ 0.00%
-+ 0.00%
-+ 0.00%

REGENERON TO HIGHLIGHT ADVANCES AT ASCO WITH PHASE 3 ADJUVANT LIBTAYO® (CEMIPLIMAB) CSCC UPDATES AND PROMISING EARLY BLOOD CANCER DATA WITH LINVOSELTAMAB COMBINATION

Reuters·05/01/2025 13:30:00

Please log in to view news